secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001639691-24-000139
Event type: regulatory
Sentiment:  negative
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact
--------------------------------------------------------------------------------

- CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.
- LivaNova says it is disappointed by the decision but does not expect any impact on its business.
- The company plans to continue pursuing improved reimbursement for VNS Therapy for DRE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000139/0001639691-24-000139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000139/livn-20241101.htm
  HTML page:      https://secwatch.observer/filing/0001639691-24-000139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer